[SCHEDULE 13G] Immuneering Corp SEC Filing

Rhea-AI Filing Summary

HBM Healthcare Investments (Cayman) Ltd. filed a Schedule 13G reporting beneficial ownership of 3,646,304 shares of Immuneering Corp Class A common stock, representing approximately 5.7% of the 63,483,397 shares outstanding as of September 30, 2025. The filing states the shares were not acquired to change or influence control of the company and that voting and investment power is exercised by HBM's board.

The reporting person is organized in the Cayman Islands and lists sole voting and dispositive power over all reported shares. The statement includes a signature by Jean-Marc LeSieur, Managing Director, dated 10/03/2025.

Positive

• Material disclosure of a >5% position: 3,646,304 shares (5.7%)
• Clear statement that shares were not acquired to change control
• Sole voting and dispositive power over the reported shares

Negative

• None.

Insights

Institutional Ownership Analyst

HBM holds a material 5.7% stake in Immuneering (IMRX).

HBM Healthcare Investments (Cayman) Ltd. reports beneficial ownership of 3,646,304 Class A shares, equal to 5.7% of outstanding stock based on 63,483,397 shares. Ownership above 5% triggers Schedule 13G reporting and signals an observable institutional position.

The filer certifies the stake was not acquired to change control and that voting and disposition powers are held solely by the reporting entity's board. This clarifies intent and governance over the position.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Immuneering Corp

(Name of Issuer)

Class A Common Stock, par value $0.001 per share

(Title of Class of Securities)

45254E107

(CUSIP Number)

09/26/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 45254E107

1

Names of Reporting Persons

HBM Healthcare Investments (Cayman) Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,646,304.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,646,304.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,646,304.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd. (the "Board"). The Board consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D., and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Immuneering Corp
(b)	Address of issuer's principal executive offices: 245 Main St., Second Floor, Cambridge, MA, 02142
Item 2.
(a)	Name of person filing: HBM Healthcare Investments (Cayman) Ltd. (the "Reporting Person")
(b)	Address or principal business office or, if none, residence: Governors Square, 23 Lime Tree Bay Avenue, PO Box 30852, Grand Cayman, KY1-1204, Cayman Islands
(c)	Citizenship: Cayman Islands, British West Indies
(d)	Title of class of securities: Class A Common Stock, par value $0.001 per share
(e)	CUSIP No.: 45254E107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of the date hereof, the Reporting Person may be deemed the beneficial owner of 3,646,304 shares of Class A Common Stock, which represent approximately 5.7% of the shares of Class A Common Stock outstanding. The percentage set forth herein is calculated based on 63,483,397 shares of Class A Common Stock outstanding as of September 30, 2025, based on information received from the Issuer.
(b)	Percent of class: 5.7%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,646,304
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3,646,304
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

HBM Healthcare Investments (Cayman) Ltd.

Signature:	/s/ Jean-Marc LeSieur
Name/Title:	Jean-Marc LeSieur, Managing Director
Date:	10/03/2025

FAQ

What stake does HBM Healthcare Investments (Cayman) Ltd. report in IMRX?

The filer reports beneficial ownership of 3,646,304 Class A shares, representing approximately 5.7% of shares outstanding.

Does the 13G filing indicate HBM intends to control Immuneering (IMRX)?

No. The filing includes a certification that the shares were not acquired and are not held to change or influence control of the issuer.

Who exercises voting and investment power over the reported IMRX shares?

Voting and investment power is exercised by the board of HBM Healthcare Investments (Cayman) Ltd.; no individual board member has sole power.

What reference share count was used to calculate the 5.7% stake in IMRX?

The percentage is calculated using 63,483,397 shares of Class A common stock outstanding as of September 30, 2025.

When was the Schedule 13G for HBM's IMRX position signed?

The filing is signed by Jean-Marc LeSieur, Managing Director, with a signature date of 10/03/2025.